This Amedeo Smart survey is supported by AngelsInitiative.com.
AmedeoTuberculosis |
|
Free Subscription
J Antimicrob Chemother |
- December 2025
- UEAPHONGSUKKIT T, Udomkarnjananun S, Vanichanan J, Jutivorakool K, et al
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients.
J Antimicrob Chemother. 2025 Dec 16:dkaf439. doi: 10.1093.
>> Share
August 2025 - GELE T, Atwine D, Baudin E, Muyindike W, et al
Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study.
J Antimicrob Chemother. 2025 Aug 29:dkaf319. doi: 10.1093.
>> Share
- SAMUELSSON T, Lonnermark E, Sundell J, Yilmaz A, et al
Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index.
J Antimicrob Chemother. 2025 Aug 21:dkaf300. doi: 10.1093.
>> Share
- VAN DER FELTZ I, Wen H, Aarnoutse RE, Magis-Escurra C, et al
Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology.
J Antimicrob Chemother. 2025 Aug 14:dkaf274. doi: 10.1093.
>> Share
- KOELE SE, Stoycheva K, Mtweve C, Manyama C, et al
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.
J Antimicrob Chemother. 2025;80:2305-2313.
>> Share
- SHAFIQ N, Kumar A, Vohra V, Khuller GK, et al
Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial.
J Antimicrob Chemother. 2025;80:2100-2108.
>> Share
May 2025 - KOELE SE, Heinrich N, De Jager VR, Dreisbach J, et al
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
J Antimicrob Chemother. 2025;80:1315-1323.
>> Share
April 2025 - METARFI Y, Chellal W, Ben Khadda Z, Hoummani H, et al
Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review.
J Antimicrob Chemother. 2025 Apr 21:dkaf126. doi: 10.1093.
>> Share
- KANG SW, Jang HM, Chang E, Bae S, et al
Impact of fluoroquinolone exposure on the diagnosis and prognosis of tuberculosis in immunocompromised patients: a propensity-score-matched, competing risk analysis.
J Antimicrob Chemother. 2025 Apr 7:dkaf111. doi: 10.1093.
>> Share
February 2025 - LIU W, Xu N, Li W, Mak WY, et al
Pharmacokinetics and safety of rifapentine in children: dosing for latent tuberculosis infection.
J Antimicrob Chemother. 2025 Feb 13:dkaf029. doi: 10.1093.
>> Share
January 2025 - CHEN S, Shang Y, Zheng J, Huo F, et al
In vitro monitoring of drug resistance emergence during stepwise induction of bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic analysis.
J Antimicrob Chemother. 2025;80:262-269.
>> Share
December 2024 - LI X, Qi X, Wang B, Fu L, et al
Efficacy of nintedanib as a host-directed therapy candidate in the treatment of tuberculosis.
J Antimicrob Chemother. 2024 Dec 4:dkae429. doi: 10.1093.
>> Share
November 2024 - AGIBOTHU KUPPARAM HK, Shah I, Chandrasekaran P, Mane S, et al
Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant TB: a multicentre observational study from India.
J Antimicrob Chemother. 2024;79:2939-2947.
>> Share
October 2024 - LIN YJ, Zou Y, Karlsson MO, Svensson EM, et al
A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB.
J Antimicrob Chemother. 2024;79:2561-2569.
>> Share
August 2024 - WALTER K, Te Brake LHM, Lemm AK, Hoelscher M, et al
Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures.
J Antimicrob Chemother. 2024 Aug 7:dkae266. doi: 10.1093.
>> Share
- WIJK M, Gausi K, Malatesta S, Weber SE, et al
The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs.
J Antimicrob Chemother. 2024;79:2022-2030.
>> Share
June 2024 - KARAKITSIOS E, Dokoumetzidis A
Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling.
J Antimicrob Chemother. 2024;79:1362-1371.
>> Share
April 2024 - PHAISAL W, Albitar O, Chariyavilaskul P, Jantarabenjakul W, et al
Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
J Antimicrob Chemother. 2024 Apr 25:dkae059. doi: 10.1093.
>> Share
- STEMKENS R, Mouhdad C, Franssen EJF, Touw D, et al
Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations.
J Antimicrob Chemother. 2024 Apr 6:dkae105. doi: 10.1093.
>> Share
- VAN INGEN J
Why do we use 100 mg of clofazimine in TB and NTM treatment?
J Antimicrob Chemother. 2024;79:697-702.
>> Share
March 2024 - YUNIVITA V, Gafar F, Santoso P, Chaidir L, et al
Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.
J Antimicrob Chemother. 2024 Mar 9:dkae057. doi: 10.1093.
>> Share
December 2023 - COMBRINCK J, Tshavhungwe P, Rohlwink U, Enslin N, et al
Rifampicin and protein concentrations in paired spinal versus ventricular cerebrospinal fluid samples of children with tuberculous meningitis.
J Antimicrob Chemother. 2023 Dec 15:dkad371. doi: 10.1093.
>> Share
September 2023 - MOK S, Roycroft E, Flanagan PR, Wagener J, et al
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.
J Antimicrob Chemother. 2023 Sep 23:dkad252. doi: 10.1093.
>> Share
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016
